Actualités Pharming Group NV - PHAR | Actions NASDAQ

Outils de qualité professionnelle, pour des investisseurs individuels.

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare...

Pharming Group Notice of H1 2022 Results

Pharming Group Notice of H1 2022 Results PR Newswire LEIDEN, Netherlands, July 25, 2022 LEIDEN, Netherlands, July 25, 2022 /PRNewswire/...

Pharming Group to present at Jefferies Healthcare Conference 2022

Pharming Group to present at Jefferies Healthcare Conference 2022 PR Newswire LEIDEN, The Netherlands, June 2...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 6-KREPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR...

Pharming Group: all proposals Annual General Meeting of Shareholders approved

Pharming Group: all proposals Annual General Meeting of Shareholders approved PR Newswire LEIDEN, Netherlands...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 6-KREPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR...

Pharming Group reports financial results for the first quarter of 2022

Pharming Group reports financial results for the first quarter of 2022 PR Newswire LEIDEN, Netherlands, May...

Pharming Group Notice of Q1 2022 Results

Pharming Group Notice of Q1 2022 Results PR Newswire LEIDEN, Netherlands, May 5, 2022 LEIDEN, Netherlands, May...

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 6-KREPORT OF FOREIGN PRIVATE ISSUERPURSUANT TO RULE 13a-16 OR...

Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRA

Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHAR)

Outils de qualité professionnelle, pour des investisseurs individuels.

PHAR Actualités

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS

Pharming Group Notice of H1 2022 Results

Pharming Group to present at Jefferies Healthcare Conference 2022

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming Group: all proposals Annual General Meeting of Shareholders approved

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming Group reports financial results for the first quarter of 2022

Pharming Group Notice of Q1 2022 Results

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRA

Pharming announces change in its holding in BioConnection following a substantial investment by new investor

Annual and Transition Report (foreign Private Issuer) (20-f)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Pharming Group NV (PHAR) Actualités

Pharming Group NV (PHAR)

Outils de qualité professionnelle, pour des investisseurs individuels.

PHAR Actualités

Pharming Group Receives Accelerated Assessment in Europe for leniolisib for the Treatment of Rare Immunodeficiency, APDS

Pharming Group Notice of H1 2022 Results

Pharming Group to present at Jefferies Healthcare Conference 2022

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming Group: all proposals Annual General Meeting of Shareholders approved

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming Group reports financial results for the first quarter of 2022

Pharming Group Notice of Q1 2022 Results

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Pharming receives agreement of Paediatric Investigation Plan and Promising Innovative Medicine designation for leniolisib from UK MHRA

Pharming announces change in its holding in BioConnection following a substantial investment by new investor

Annual and Transition Report (foreign Private Issuer) (20-f)

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application